Global SCIG Market 2026 evolving with immunotherapy advancements

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Valuation Is Forecasted For The Subcutaneous Immunoglobulin (SCIG) Market By 2030 Starting From Its 2026 Size?

The subcutaneous immunoglobulin (scig) market has experienced significant expansion recently. Its size is projected to increase from $14.39 billion in 2025 to $16.32 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 13.4%. This historical growth can be linked to several factors, including the increasing diagnosis of primary immunodeficiency disorders, the limitations associated with intravenous immunoglobulin therapy, a growing demand for long-term immune support, the enhanced safety profile of scig, and patients’ increasing preference for at-home care.

The market for subcutaneous immunoglobulin (scig) is projected to experience substantial expansion over the coming years, reaching a valuation of $25.71 billion by 2030, propelled by a compound annual growth rate (CAGR) of 12.0%. This anticipated growth during the forecast period stems from several factors, including the broadened applications of scig beyond immunodeficiency, a heightened emphasis on homecare solutions in healthcare, innovations in infusion technology, the increasing incidence of autoimmune and neurological conditions, and a greater need for treatment approaches centered around the patient. Key trends expected within this period encompass a noticeable transition from intravenous immunoglobulin (IVIG) to scig treatments, an uptick in the use of immunoglobulin therapy delivered at home, a growing inclination towards self-administering devices, the expanded utilization of scig for chronic immune conditions, and an elevated requirement for sustained immune replacement therapy.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=15935&type=smp

What Major Growth Drivers Are Shaping The Outlook Of The Subcutaneous Immunoglobulin (SCIG) Market?

The rise in secondary immunodeficiency diseases is projected to boost the subcutaneous immunoglobulin market. These conditions involve a weakened or impaired immune system stemming from factors external to the immune system itself. Key drivers for the prevalence of secondary immunodeficiency diseases include an aging demographic, the use of immunosuppressive therapies, and exposure to environmental toxins. Subcutaneous immunoglobulin therapy delivers antibodies to reinforce the compromised immune system, particularly in long-term conditions like HIV or autoimmune diseases, thereby guarding against infections and assisting immunological function throughout treatment. For example, according to HIV i-Base in October 2024, new HIV diagnoses in 2023 rose by 36% for heterosexual men, from 445 in 2022 to 605, and by 30% for heterosexual women, increasing from 602 in 2022 to 780. Consequently, the growing occurrence of secondary immunodeficiency diseases is stimulating growth in the subcutaneous immunoglobulin market.

Which Segment Categories Define The Subcutaneous Immunoglobulin (SCIG) Market?

The subcutaneous immunoglobulin (scig) market covered in this report is segmented –

1) By Product Type: Immunoglobulin A (IgA), Immunoglobulin G (IgG)

2) By Application: Primary Immunodeficiency Disorders, Autoimmune Diseases, Neurological Disorders, Other Applications

3) By End-Use: Clinics, Hospitals, Homecare, Other End-Uses

Subsegments:

1) By Immunoglobulin A (IgA): IgA1, IgA2

2) By Immunoglobulin G (IgG): IgG1, IgG2, IgG3, IgG4

What Major Market Trends Are Driving Changes In The Subcutaneous Immunoglobulin (SCIG) Market?

Major companies within the subcutaneous immunoglobulin (SCIG) market are increasingly focused on developing advanced solutions, including ready-to-use prefilled formulations, to enhance the convenience of treatment, facilitate self-administration, and improve the overall patient experience. These ready-to-use SCIG formulations represent premeasured, stable immunoglobulin products specifically designed for subcutaneous delivery, enabling individuals with primary immunodeficiency and other immune disorders to administer their therapy more easily away from clinical environments. An illustrative instance occurred in April 2023, when the U.S. Food and Drug Administration (FDA) approved a 50 mL / 10 g prefilled syringe presentation of Hizentra (Immune Globulin Subcutaneous [Human] 20%), thereby providing patients with a simplified, ready-to-use option that supports more convenient home infusion and strengthens treatment adherence.

Who Are The Top Companies Competing In The Subcutaneous Immunoglobulin (SCIG) Market?

Major companies operating in the subcutaneous immunoglobulin (scig) market are CSL Behring, Grifols S.A., Octapharma AG, Kedrion Biopharma, LFB Group, Biotest AG, Bio Products Laboratory Ltd., ADMA Biologics Inc., Kamada Pharmaceuticals, Takeda Pharmaceutical Company Limited, Baxter International Inc., Bharat Serums and Vaccines Limited, Emergent BioSolutions Inc., Pfizer Inc., Johnson & Johnson, Lonza Group, Argenx SE, CinnaGen Co., Intas Pharmaceuticals Ltd., Dr. Reddy’s Laboratories Ltd.

Read the full subcutaneous immunoglobulin (scig) market report here:

https://www.thebusinessresearchcompany.com/report/subcutaneous-immunoglobulin-scig-global-market-report

Which Regions Are Projected To Dominate The Subcutaneous Immunoglobulin (SCIG) Market In The Coming Years?

North America was the largest region in the subcutaneous immunoglobulin market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the subcutaneous immunoglobulin (scig) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Subcutaneous Immunoglobulin (SCIG) Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=15935&type=smp

Browse Through More Reports Similar to the Global Subcutaneous Immunoglobulin (SCIG) Market 2026, By The Business Research Company

Subcutaneous Immunoglobulin Scig Market Report 2026

https://www.thebusinessresearchcompany.com/report/subcutaneous-immunoglobulin-scig-global-market-report

Immunoglobulins Market Report 2026

https://www.thebusinessresearchcompany.com/report/immunoglobulins-global-market-report

Intravenous Immunoglobulin Market Report 2026

https://www.thebusinessresearchcompany.com/report/intravenous-immunoglobulin-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795